Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Stage IIIA Rectal Cancer AJCC v8: early-phase trial registry
4 of 9 indexed Stage IIIA Rectal Cancer AJCC v8 trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,916 of 28,707 conditions by registered trial count.
9 US clinical trials · 4 currently recruiting · #1,916 of 28,707 conditions by registered trial count
Stage IIIA Rectal Cancer AJCC v8: 9 US clinical trials tracked, 4 recruiting.
Stage IIIA Rectal Cancer AJCC v8 is the subject of 9 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 4 of these trials.
Enrollment posture brief
Registry condition stage-iiia-rectal-cancer-ajcc-v8
OPEN 4 | RECR 44% | LATE 0 | EARLY 7 | RANK #1916 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Acute Ischemic Stroke (44% recruiting · 27 trials)
Stage IIIA Rectal Cancer AJCC v8 lists 4 open slots (44% of 9 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Stage IIIA Rectal Cancer AJCC v8 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Stage IIIA Rectal Cancer AJCC v8 is recruiting below its size-band peers.
4 of 9 indexed trials (44.4%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Stage IIIA Rectal Cancer AJCC v8 research.
M.D. Anderson Cancer Center accounts for 4 of 9 trials (44.4%). 5 distinct sponsors appear on at least one study for this condition label.
-
Most Stage IIIA Rectal Cancer AJCC v8 trials plan to enrol fewer than 100 people.
Median target enrolment is 46 among the 9 trials that report a genuine target (sentinel values excluded). 7 of those (77.8%) plan for fewer than 100 participants.
-
Stage IIIA Rectal Cancer AJCC v8 research is mostly interventional.
7 interventional and 2 observational studies make up this index (77.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
9 total, page 1 of 1
Active Surveillance and Chemotherapy Before Surgery in Treating Participants With Stage II-III Rectal Cancer
M.D. Anderson Cancer Center
NCT03594630
Establishing a ctDNA Biomarker to Improve Organ Preserving Strategies in Patients With Rectal Cancer
OHSU Knight Cancer Institute
NCT05081024
Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer
Jonsson Comprehensive Cancer Center
NCT04703101
An Investigational Scan (64Cu-Labeled M5A Antibody) in Combination With SOC Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer
City of Hope Medical Center
NCT05245786
Circulating Tumor Cells in Patients With Locally Advanced Rectal Cancer
M.D. Anderson Cancer Center
NCT02874885
SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial
M.D. Anderson Cancer Center
NCT04599140
LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
NCT04616183
TAS-102 With Concurrent Radiation for the Treatment of Untreated Resectable Stage II-III Rectal Cancer
OHSU Knight Cancer Institute
NCT04104139
Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer
Academic and Community Cancer Research United
NCT03992456
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Stage IIIA Rectal Cancer AJCC v8 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Stage IIIA Rectal Cancer AJCC v8 trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Stage IIIA Rectal Cancer AJCC v8 page
9 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 Stage IIIA Rectal Cancer AJCC v8 trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Stage IIIA Rectal Cancer AJCC v8 trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Stage IIIA Rectal Cancer AJCC v8 condition card totals 9 registered trials; most-linked intervention Trifluridine and Tipiracil Hydrochloride; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.